← Oncology Approval Tracker

FDA DECISION ·

Enhertu

fam-trastuzumab deruxtecan-nxki · Daiichi Sankyo

FDA approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with unresectable or metastatic HER2-low breast cancer (IHC 1+ or IHC 2+/ISH-negative) after chemotherapy in the metastatic setting or recurrence during or within six months after completing adjuvant chemotherapy.

LAMPGEN ANALYSIS

Why it matters

The action makes HER2-low a treatment-selection category separate from classic HER2-positive disease.

What research teams should watch

Record the underlying IHC score and ISH result rather than relying on a binary HER2 status field.

PRIMARY RECORDS

Sources